PeptidePreclinical
Cartalax
Also known as: AED peptide, T-31, Sigumir, Kartalaks
Bioregulatory Tripeptide | Cartilage & Connective Tissue Support
Overview
Synthetic tripeptide developed by Professor Vladimir Khavinson, supporting cartilage, connective tissue, and cellular regeneration through proliferation markers and apoptosis pathway modulation.
Key benefits
- Joint and connective tissue support
- Potential anti-aging effects on fibroblasts
- Cartilage regeneration support
- Established safety profile in Russian clinical practice
Mechanism of action
Modulates cell proliferation, suppresses apoptosis, affects fibroblast activity, reduces senescence markers, and influences extracellular matrix preservation.
Molecular data
- Type
- Tripeptide
- Half-life
- Minutes (short peptide); effects persist via epigenetic changes
Sequence
Ala-Glu-Asp (AED)
Indications
What the research community uses this compound for, with self-reported effectiveness.
Joint Health
Skin Health
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 100-200mcg (1-2 capsules) | 1-2x daily with meals | — |
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 700-1400mcg (10-20mcg/kg) | Daily | — |
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 0.5-1ml solution | 2x daily | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- No reported side effects in Russian clinical use when taken properly
- Well-tolerated in elderly patients
Contraindications
- Pregnancy and breastfeeding
- Active cancer (theoretical proliferation risk)
Monitoring
- Follow official Russian manufacturer timing guidelines
- Take with meals for oral form